SouthState Corp’s Neos Therapeutics, Inc NEOS Stock Holding History

SouthState Corp’s Portfolio NEOS Stock Details NEOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-100	Closed	–	–	356
2020 Q3	$0	Buy	+100	New	+$68	﹤0.01%	350

Other funds holding NEOS

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SouthState Corp's NEOS Position: Q4 2020 in Review

SouthState Corp sold out of Neos Therapeutics, Inc (NEOS) in Q4 2020, closing a stake of 100 shares.

SouthState Corp first reported a position in NEOS in Q3 2020 and held it in 1 quarter. The position peaked at $0 in Q3 2020. 37 funds tracked by Wall St. Rank hold NEOS as of Q4 2020.

SouthState Corp reported no remaining Neos Therapeutics, Inc position as of Q4 2020 after selling out during the quarter.
SouthState Corp sold 100 Neos Therapeutics, Inc shares in Q4 2020.
SouthState Corp first reported a position in Neos Therapeutics, Inc in Q3 2020 and held it in 1 quarter.
SouthState Corp's Neos Therapeutics, Inc position peaked at $0 in Q3 2020.
37 funds tracked by Wall St. Rank held Neos Therapeutics, Inc as of Q4 2020.

Based on SouthState Corp's 13F filing for Q4 2020, filed 10 Feb 2021.